The population’s attitudes to colorectal cancer screening in the Czech Republic
Authors:
N. Král 1; B. Seifert 1; Š. Suchánek 2; M. Zavoral 2; O. Májek 3
Authors place of work:
Univerzita Karlova, 1. LF, Ústav všeobecného lékařství, Praha
1; Univerzita Karlova, 1. LF, Ústřední vojenská nemocnice, Praha
2; Masarykova univerzita, Institut biostatistiky a analýz, Brno
3
Published in the journal:
Epidemiol. Mikrobiol. Imunol. 64, 2015, č. 1, s. 41-46
Category:
Review articles, original papers, case report
Summary
Background:
The mortality of colorectal cancer (CRC) is significant worldwide. There is good evidence for benefits of the CRC screening in mortality reduction. Since 2009, the population of the Czech Republic have had two CRC screening options from which to choose: a faecal occult blood test (FOBT) at the age of 50 to be repeated every two years or primary screening colonoscopy (PSC) at the age of 55. General practitioners play a crucial role in the CRC screening programme. The CRC screening adherence of the Czech population is poor and does not exceed 25%.
Material and Methods:
The aims of the study were to analyse the reasons behind the low CRC screening adherence of the Czech population, to classify the population’s attitudes, and to identify the barriers. A questionnaire survey was conducted in a Czech energy company with 13,000 employees in 2011–2012. The questionnaire was administered electronically by e-mail or directly at the workplace.
Results:
The questionnaire response rate was 31.3% (4070). The pool of respondents consisted of 2804 (68.9%) females and 1266 (31.1%) males. Of the respondents, 1345 (33.1%) were aged over 50 years (73.5% women and 26.5% men). Of the cohort aged over 50, 68.65% of women and 63.2% of men took a FOBT. Ten percent of respondents aged over 50 years have never heard of CRC screening and 32.8% of this age category have never participated in CRC screening. The main reasons for not taking a FOBT were feeling well and having no health problems (38.8%) or FOBT not offered the by the general practitioner (27.8%). Other reasons were no time to do so, fear of the result, unsure of the procedure, unawareness of what FOBT is, or uncomfortable about the test procedure. On the other hand, 8.37% of the participants aged between 15 and 39 years and 20.7% of those aged between 40 and 49 years have already taken a FOBT. Overall, 15.4% of respondents prefer the new alternative, PSC, as the CRC screening option. Significant differences in CRC screening adherence are seen between administrative regions of the Czech Republic and between education levels.
Conclusions:
From the results, it follows that a considerable proportion of the population of the Czech Republic do not understand the principle of CRC screening and its methods. Enough room has been left to promote education on CRC screening for both the public and general practitioners. On the other hand, a large part of proactive individuals participate in CRC screening before the age of 50.
Keywords:
colorectal cancer – screening – general practitioner – population – patient
Zdroje
1. Dusek L, et al. Epidemiology, prevention and treatment of Colorectal cancer based on available studies and data. Prague: University Hospital Motol;2012.
2. Majek O, Danes J, Zavoral M, et al. Czech National Cancer Screening Programmes in 2010. Klinická Onkologie, 2010;23(5):343–53.
3. Majek O, Danes J, Skovajsova M, et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health, 2011;11:288.
4. Zavoral M, Suchanek S, Zavada F, et al. Colorectal cancer screening in Europe. World Journal of Gastroenterology, 2009;15(47):5907–5915.
5. Kral N, Seifert B. Změny ve screeningu kolorektálního karcinomu - krok správným směrem? Onkologie, 2010;4(4):251–255.
6. Vernon SW, Meissner H, Klabunde C, et al. Measures for ascertaining use of colorectal cancer screening in behavioral, health services, and epidemiologic research. Cancer Epidemiology Biomarkers Prevention, 2004;13(6):898–905.
7. Jepson R, Clegg A, Forbes C, et al. The determinants of screening uptake and interventions for increasing uptake: a systematic review. Health Technol Assess, 2000;4(14):1–133.
8. Wardle J, Sutton S, Williamson S, et al. Psychosocial influences on older adults‘ interest in participating in bowel cancer screening. Prev Med, 2000;31(4):323–334.
9. Hudson SV, Ohman-Strickland P, Cunningham R, et al. The effects of teamwork and system support on colorectal cancer screening in primary care practices. Cancer Detect Prev, 2007;31(5):417–423.
10. Lawsin C, DuHamel K, Itzkowitz SH, et al. Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer. Support Care Cancer, 2007;15(5):557–564.
11. European Colorectal Cancer Screening Guidelines Working Group, European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy, 2013;45(1):51–59.
12. Denters M, Deutekom M, Fockens P, et al. Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands. BMC Gastroenterology, 2009;9:28.
13. Berchi C, Guittet L, Bouvier V, et al. Cost-effectiveness analysis of the optimal threshold of an automated immunochemical test for colorectal cancer screening: performances of immunochemical colorectal cancer screening. Int J Technol Assess Health Care, 2010;26(1):48–53.
14. Colonoscopy and colorectal cancer screening strategies. Committee Opinion No 482. American College of Obstetricians and gynecologists. Obstet Gyencol, 2011;117:766–771.
15. Kuipers EJ, Rösch T, Bretthauer M, et al. Colorectal cancer screening-optimizing current strategies and new directions. Nat Rev Clin Oncol, 2013;10(3):130–142.
16. Zavoral M, Fric P, Suchanek S, et al. National screening program for sporadic colorectal cancer: Development, Present and Perspective, Health News. Gastroenterology, 2013;16–19.
17. Skovajsova M, et al. Screening of breast carcinoma screening in the Czech Republic requires cooperation with surgeons. Rozhl Chir, 2012;91(3):121–131.
18. Menees SB, Patel DA, Dalton V, et al. Colorectal cancer screening practices among obstetrician/gynecologists and nurse practitioners. J Womens Health, 2009;18(8):1233–1238.
19. Gregory, et al. Demographic, social cognitive and social ecological predictors of intention and participation in screening for colorectal cancer. BMC Public Health, 2011;11–38.
20. Menees SB, Inadomi J, Elta G, et al. Colorectal Cancer Screening Compliance and Contemplation in Gynecology Patients, JWH, 2010;911–916.
21. Frederiksen BL, Jørgensen T, Brasso K, et al. Socioeconomic position and participation in colorectal cancer screening. Br J Cancer, 2010;103(10):1496–1501.
22. Bae N, Park S, Lim S, et al. Factors associated with adherence to fecal occult blood testing for colorectal cancer screening among adults in the Republic of Korea. Eur J Oncol Nurs, 2014;18(1):72–77.
23. Bapuji S, Lobchuk M, McClement S, et al. Fecal occult blood testing instructions and impact on patient adherence. Cancer Epidemiol, 2012;36(4):e258–264.
24. Fiscella K, Yosha A, Hendren S, et al. Get screened: a pragmatic randomized controlled trial to increase mammography and colorectal cancer screening in a large, safety net practice. BMC Health Serv Res, 2010;10:280.
25. Lobchuk M, Bapuji S, McClement S, et al. What is the role of family in promoting faecal occult blood test screening? Exploring physician, average-risk individual, and family perceptions. Cancer Epidemiol, 2012;36(3):190–199.
26. Zauber A, Lansdorp-Vogelaar I, Knudsen A, et al. Evaluating Test Strategies for Colorectal Cancer Screening – Age to Begin, Age to Stop, and Timing of Screening Intervals: A Decision Analysis of Colorectal Cancer Screening for the U.S. Preventive Services Task Force from the Cancer Intervention and Surveillance Modeling. Rockville: USA;2009.
27. Viguier J, Calazel-Benque A, Eisinger F, et al. Organized colorectal cancer screeing programmes: how to optimize efficiency among general practitioners. European Jounal of Cancer Prevention, 2011;20 Suppl 1:S26–32.
28. Worthley D, Cole S, Esterman A, et al. Screening for colorectal cancer by faecal occult blood test: why people choose to refuse. Intern Med J, 2006;36(9):607–610.
29. Lo S, Waller J, Wardle J, et al. Comparing barriers to colorectal cancer screening with barriers to breast and cervical screening: a population-based survey of screening-age women in Great Britain. J Med Screen, 2013;20(2):73–79.
30. Debarros M, Steele S, et al. Colorectal cancer screening in an equal access healthcare system. J Cancer, 2013;4(3):270–280.
31. Tastan S, Andsoy I, Iyigun E, et al. Evaluation of the knowledge, behavior and health beliefs of individuals over 50 regarding colorectal cancer screening. Asian Pac J Cancer Prev, 2013;14(9):5157–5163.
32. Haggstrom D, Klabunde C, Smith J, et al. Variation in primary care physicians‘ colorectal cancer screening recommendations by patient age and comorbidity. J Gen Intern Med, 2013;28(1):18–24.
33. Dreier M, Borutta B, Seidel G, et al. Leaflets and websites on colorectal cancer screening and their quality assessment from experts’ views. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2014;57(3):356–365.
34. Fortuna R, Idris A, Winters P, et al. Get Screened: A Randomized Trial of the Incremental Benefits of Reminders, Recall, and Outreach on Cancer Screening. J Gen Intern Med, 2014;29(1):90–97.
35. Tinmouth J, Ritvo P, McGregor S, et al. ColonCancerCheck Primary Care Invitation Pilot project: family physician perceptions. Can Fam Physician, 2012;58(10):e570–577.
36. Liss D, Petit-Homme A, Feinglass J, et al. Adherence to repeat fecal occult blood testing in an urban community health center network. J Community Health, 2013;38(5):829–833.
37. Centers for Disease Control and Prevention (CDC). Vital signs: colorectal cancer screening test use – United States, Morb Mortal Wkly Rep, 2013;8;62(44):881–888.
38. Charters T, Strumpf E, Sewitch M, et al. Effectiveness of an organized colorectal cancer screening program on increasing adherence in asymptomatic average-risk Canadians. BMC Health Serv Res, 2013;13:449.
39. Aarts M, Lemmens V, Louwman M, et al. Socioeconomic status and changing inequalities in colorectal cancer? A review of the associations with risk, treatment and outcome. Eur J Cancer, 2010;46(15):2681–2695.
40. Ferrat E, Le Breton J, Veerabudun K, et al. Colorectal cancer screening: factors associated with colonoscopy after a positive faecal occult blood test. Br J Cancer, 2013;109(6):1437–444.
41. Van Agt H, Korfage I, Essink-Bot M, et al. Interventions to enhance informed choices among invitees of screening programmes – a systematic review. Eur J Public Health, 2014, published online.
42. Cole S, Young G, Byrne D, et al. Participation in screening for colorectal cancer based on a faecal occult blood test is improved by endorsement by the primary care practitioner. J Med Screen, 2002;9(4):147–152.
43. Tinmouth J, Ritvo P, McGregor E, et al. A qualitative evaluation of strategies to increase colorectal cancer screening uptake. Can Fam Physician. 2011;57(1): e7–e15.
44. Weller D, Coleman D, Robertson R, et al. The UK colorectal cancer screening pilot: results of the second round of screening in England. 2007;97(12):1601–1605.
45. Denters M, Deutekom M, Bossuyt P, et al. Involvement of previous non-participants cannot fully compensate for lower participation in a second round of FIT-screening. Cancer Epidemiol, 2013;37(3):330–335.
46. Haack G, Köster M, Töppich J, et al. Information on early detection of colorectal cancer : Development of an information module for the Women‘s Health Portal of the Federal Center for Health Education (BZgA). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2014;57(3):380–387.
47. Huang J, Shi L, et al. Differences in behavioral outcomes between first-year and second-year participants in a community-based colorectal cancer education intervention. Asian Pac J Cancer Prev, 2011;12(12):3323–3329.
48. Clouston K, Katz A, Martens P, et al. CIHR/CCMB Team in Primary Care Oncology (PCO-NET). Does access to a colorectal cancer screening website and/or a nurse-managed telephone help line provided to patients by their family physician increase fecal occult blood test uptake?: A pragmatic cluster randomized controlled trial study protocol. BMC Cancer, 2012;12:182.
49. Seeff L, Nadel M, Klabunde C, et al. Patterns and predictors of colorectal cancer test use in the adult U.S. population. Cancer, 2004;100(10):2093–2103.
50. Cogbill S, Francis B, Thompson V, et al. Factors Affecting African American Men’s Use of Online Colorectal Cancer Education. J Cancer Educ, 2014;29(1):25–29.
51. Smith S, Blumenthal D et al. Efficacy to effectiveness transition of an Educational Program to Increase Colorectal Cancer Screening (EPICS): study protocol of a cluster randomized controlled trial. Implement Sci, 2013;8:86.
52. Brawarsky, P, Brooks D, Mucci, et al. Effect of physician recommendation and patient adherence on rates of colorectal cancer testing. Cancer Detection and Prevention, 2004;28(4):260–268.
53. Senore C, Malila N, Minozzi S, et al. How to enhance physician and public acceptance and utilisation of colon cancer screening recommendations. Best Pract Res Clin Gastroenterol, 2010;24(4):509–520.
Štítky
Hygiene and epidemiology Medical virology Clinical microbiologyČlánok vyšiel v časopise
Epidemiology, Microbiology, Immunology
2015 Číslo 1
Najčítanejšie v tomto čísle
- Macrolide resistance in Treponema pallidum subsp. pallidum in the Czech Republic and in other countries
- Contribution of the detection of IgA antibodies to the laboratory diagnosis of mumps in the population with a high vaccination coverage
- Minimum inhibitory concentrations of erythromycin and other antibiotics for Czech strains of Bordetella pertussis
- A case of tuberculous meningitis associated with persistently reduced CD4+ T lymphocyte counts